Abstract The present invention relates to novel crystalline form of 5-fluoro-3-phenyl-2-[(lS)-l-(9H-purin-6-ylamino)propyl]quinazolin-4(3H)-one compound of formula-1 and process for its preparation thereof, represented by the following structural formula:

The present invention relates to a pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts.

The present invention relates to an amorphous form of 4-methyl-N-[3-(4-methyl-1H-imidazol-l-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide compound of formula-1, which is represented by the following structural formula

The present invention relates to novel polymorphs of (i?)-8-chloro-l-methyl-2,3,4,5-tetrahydro-l#-3-benzazepine hydrochloride which is represented by structural formula-1 and process for its preparation.

The present invention relates to a process for the preparation of Trisodium (4-{[(lS,3R)-l-([l,l"-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(N-pentanoyl-N-{[2"-(lH-tetrazoI-l-id-5-yl)[l,r-biphenylJ-4-yl]methyl}-L-vallnate) represented by the following structural formula-1 and its poly...

The present invention relates to a process for the preparation of highly pure 5-[(1RS)-2-cyclopropyl-l-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c] pyridin-2-yl acetate as well as novel process for its intermediate

The present invention relates to improved processes for the preparation of compounds of formula-I and II, which are key intermediates for the preparation of Rosuvastatin and its pharmaceutically acceptable salts.

The present invention relates to a novel process for the preparation of Isopropyl (Z)-7-[(lR,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]-cyclopentyl]-5-heptenoate represented by structural formula-1. The present invention also relates to novel intermediates for the preparation of Isopropyl (Z)-7-[(lR,2...

The present invention relates to novel salts of benzimidazole derivatives, preferably mesylate salt of benzimidazole derivatives represented by the following structural formulas, which are useful intermediates in the synthesis of pure l-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-yl...

The present invention relates to amorphous solid dispersions of 5-chloro-N4-[2-[(l-methylethyl)sulfonyl]phenyl]-N 2,4-pyrimidinediamine compound of formula-1, represented by the following structure:

The present invention relates to a process for the preparation of Clofarabine compound of formula-1.A process for the preparation of pure Clofarabine compound of formula-1, comprising of; a) Reacting the 2-Deoxy-2-fluoro-l,2,5-tri-0-benzoyl-D-ribofuranose compound of formula-2 BzO    \ J BzCf    F Formula-2 wit...

The present invention relates to crystalline polymorph of N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4".(trifluoromethyl)[l, 1 "-biphenyl]-2-yl]carbonyl] amino]-1 -piperidinyl]butyl]-9H-fluorene-9-carboxamide methanesulfonate salt represented by the following structural formula-la and process for preparation thereof. ...

ABSTRACT The present invention relates to process for the preparation of l-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide represented by the following structural formula-1 a and polymorphs thereof.

The  present  invention  relates  to  Amorphous  form  of N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-ftiranyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its process for preparation.

The present invention relates to an improved process for the preparation of crystalline polymorphs of Rifaximin compound represented by the following structural formula-1.

Abstract The present invention relates to an improved process for the preparation of N-[6-( cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4" -(trifluoromethoxy) carboxamide diphosphate, represented by the following structural formula

The present invention relates to an improved process for the preparation of crystalline N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-]-piperazinyl]-2-methyl-4-pyrimidinyl]-amino]-5-thiazolecarboxamide monohydrate compound represented by the following structural formula-la.

The present invention relates to novel & improved processes for the preparation of antiarrhythmic agent.

The present invention relates to novel crystalline form of 5-fluoro-3-phenyl-2-[(l S)-1- (9I-I-purin—6-ylamino)propyl]quinazolin-4(3H)-one compound of formula-1 and process for its preparation thereof, represented by the following structural

Abstract The present invention relates to an improved process for the preparation of N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine represented by the folio wing structural formula-1 and its pharmaceutically acceptable salts.

The present invention relates to novel crystalline polymorph of N-[2-[(lS)-l-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]2,3-dihydro-l,3-dioxo-lH-isoindol-4-yl] acetamide represented by the following structural formula-1 and process for its preparation.

The present invention provides a process for the preparation of crystalline form-XLI of N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-lH-indazol-6-ylsulfanyl]-benzamide compound of formula-1, which is represented by the following structural formula

The present invention relates to process for the preparation of (laR,2S,5R,5aS,6S£a3,9RA

The present invention relates to novel process for the preparation of (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitriIe phosphate compound of formula-1 represented by the following structural formula:

The present invention relates to formic acid salt as well as its crystalline form of antidepressant drug i.e., 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofurancarboxamide compound of formula-1, which is useful in the preparation of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran ca...

The present invention relates to an improved process for the preparation of 5-[[[(2S)- 2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid compound of formula-1, represented by the following structural formula: ...

The present invention relates to novel polymorphs of 5-[[[(2S)-2-amino-3-[4-(amino carbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl] amino]methyl]-2-methoxybenzoic acid compound of formula-1, represented by the following structural formula:

The present invention relates to a process for the preparation of (lS)-l,5-anhydro-l-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol which is represented by the following structural formula-1 and its glycerol solvate.

The present invention relates to novel crystalline polymorphs of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-l-piperazinyl)propoxy]-3-quinoline carbonitrile represented by the following structural formula-1 and process for preparation thereof.

The present invention relates to a process for the preparation of 6,11-dihydro-l 1-(1 -methyl-4-piperidinylidene)-5H-imidazo[2,1 -b] [3 ] benzazepine-3 -carboxaldehyde compound of formula-1. The present invention also provides novel crystalline polymorph of compound of formula-1 and process for its preparation....

The present invention relates to an improved process for the preparation of GABA analogue represented by the following structural formula-1

The present invention relates to novel process for the preparation of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-moipholinyl)phenyl]-l,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide represented by the following structural formula-1. o Formula-1

The present invention relates to an improved process for the preparation of 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-y1- carboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide represented by the following structural formula-1.

The present invention provides a process for the preparation of intermediate compounds used for the preparation of (lS,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-l-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and its pharmaceutically acceptable salts thereof, represented by the following structural formula....

Abstract The present invention relates to novel processes for the preparation l,3-Thiazol-5-ylmethyl[(2R,5R)-5-{[(2S)-2-K^ carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino}-l,6-diphenylhexan-2-yl] carbamate having the following structural formula-1 and it's intermediates thereof.

Abstract The present invention relates to a solid dispersion of l,3-Thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-[(methy^^ amino]-4-(morphoIin-4-yl)butanoyl]amino}-l,6-diphenylhexan-2-yl] carbamate having the following structural formula-1 with one or more pharmaceutical acceptable carrier and process for their preparat...

The present invention relates to novel pyrimidine derivatives, process for their preparation and their use in the preparation of bis[(E)-7-[4( 4-fluorophenyl)-6-isopropyl-2[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)3,5-dihydroxyhept-6-enoic acid] or its pharmaceutically acceptable salts thereof. ...

The present invention relates to novel polymorphs and novel intermediate for l-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1 -yl)phenyl]-4,5,6,7-tetrahydro-1 H-pyrazolo [3,4-c]pyridine-3-carboxamide represented by the following structural formula-1. Formula-1

The present invention relates to a process for the preparation of ((3S,5R)-5-((lH-1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3 -yl)methyl-4-methyl benzenesulfonate compound of formula-1, which is a useful intermediate for the preparation of Triazole Antifungal drug and represented by the follo...

The present invention relates to pharmaceutical composition of moxifloxacin, its salts and/or hydrates and also relates to the method of preparation of the pharmaceutical composition.

The present invention relates to novel process for the preparation of 3-[(li?,2i?)-3-(dimethylamino)-l-ethyl-2-methylpropyl]phenol represented by structural formula-1 and its hydrochloride salt. The present invention also provides novel intermediates which are useful in the preparation of 3-[(lR,2R)-3-(dimethylamino...

The present invention relates to an amorphous solid dispersion of (15)-l,5-anhydro-l-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-P-glucitol compound of formula-1, and its process for the preparation thereof. The compound of formula-1 is represented by the following structural formula: ...

An improved process for the preparation of butyroxymethyl methyl4-(2,,3"-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate compound of formula-1. The present invention also relates to novel crystalline forms of compound of formula-1 and its intermediates thereof. Formula-1

The present invention relates to amorphous form of 5-chloro-N4-[2-[(l-meihylcthyl) sulfonyl]phenyl]-N2-[5-methyl-2-(l-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidine diamine compound of formula-1, represented by the following structure.

The present invention relates to a novel process for the preparation of N-butyl-2-((4R,6S)-6-formyl-2,2-dimethyl-l,3-dioxan-4-yl)acetamide compound of formula-1.

The present invention provides a novel polymorphic form of l-[(2,6-difluorophenyl)methyl]-lH-l,2,3-triazole-4-carboxamide compound represented by the following structural formula-1 and process for its preparation.

The present invention relates to amorphous form of 5-[[[(2S)-2-amino-3-[4-(amino carbonyD-Z.6-dimethylphenyl]-1-oxopropyl][(1S)-l-(4-phenyI-lH-imidazol-2-yl)ethyl]amino] methy1]-2-methoxy benzoic acidpompound of formulg—I, represented by the following structure:

The present invention relates to amorphous form of 5-[[[(2S)-2-amino-3-[4-(amino carbonyI)-2,6-dimethylphenyl]-1 -oxopropyl] [(1S)-1 -(4-phenyl-1 H-irnidazol-2-yl)ethyl]amino] methyl]-2-methoxy benzoic acid compound of formula-1, represented by the following structure.

Abstract The present invention relates to solid state forms of 5-fluoro-3-phenyl-2-[(lS)-1-(9H" purin-6-ylamino)propyl]quinazolin-4(3H)-one and salts-thereof-compound~of~formula-1 anc process for its preparation thereof, which is represented by the following structural formula

The present invention relates to novel crystalline polymorphs of l-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide represented by the following structural formula-la and process for preparation thereof.

The  present  invention  relates, to  a  pharmaceutical  composition  of N-(3,5- dichloropyridin-4-yl)-3 -cyclopropylmethoxy-4-difluoromethoxy-benzamide and    its preparation thereof. Further, the stable pharmaceutical composition of the present invention is for the treatment of chronic obstructive pulmonary dise...

The present invention relates to an improved process for the preparation of crystalline methanol solvate, ethanol solvate and crystalline Form-Ill of 4-(4-{3-[4-Chloro-3-(trifluorom,ethyl)phehyl]ureido}phenoxy)-N-2-methylpyridine-2-carboxamide 4-methyl benzenesulfonate compound of formula-2, which is represented by ...

The present invention relates to a process for the preparation of anticoagulant drug i.e, 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene carboxamide represented by the structural formula-1. Further, the present invention also relates to novel intermediates, which ar...

The present invention relates to an improved process for the preparation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzene sulfonamide or its pharmaceutically acceptable salts preferably hydrochloride salt represented by the compound of formula-I. Formula-I ...

The present invention relates to an improved process for the preparation of 1-[(3R)-3- [4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen- 1-one compound of formula-1 and its polymorphs thereof, which is represented by the following structural formula:

ABSTRACT:The present invention relates to an improved process for the preparation of ((2R,3R)-2-(2,4-di fluorophenyl)-3-(4-methylenepiperidin-1 yl)-1 -(IH-1,2,4-triazol-1 -yl)butan-2-ol) compound of formula-1 and its salts thereof.

ABSTRACT: The present invention relates to a novel process for the preparation of methyl[(2S)-1-{(6S)-6-(5-(9,9-difluoro-7-{2-[(lR,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbu-tanoyl} -2-azabicyclo[2.2.1 ]hept-3-yl]-1 H-benzimidazol-6-yl} -9H-ftuoren-2-yl)-1 H-imidazol -2-yl]-5-azaspiro[2.4.]hept-5-yl}-3-me...

The present invention relates to a novel process for the preparation of DPP-IV inhibitors

Abstract The present invention relates to novel process for the preparation of propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-lH-pyrrolo[253-b]pyridine-3-carbonyl]-294-difluoro-phenyl}-amide compound of formula-1, represented by thej following structure:

The present invention relates   to  process   for  the   preparation   of (1 S,3 S,7S, 1 OR, 11S, 12S, 16R)-7,11 -dihydroxy-8,8,10,12,16-pentamethyl-3-[(lE)-1 -methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione reesented by the following structural formula-1. Formula-1 The pres...

The present invention provides a novel process for the preparation of l-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-lH-indole-7-carboxamide compound represented by the following structural formula-1.

The present invention relates to 2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide monohydrochloride compound of formula-la, its hydrates, polymorphs and process for preparation thereof.

The present invention relates to amorphous solid dispersion comprising (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-4-fLuoro-3-hydroxy-4-methyl tetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate represented by the following structural formula-1 and at least one pha...

The present invention relates to novel process for the preparation of (2S)-N-((S)-l-((S)-4-methyl-1 -((R)-2-methyloxiran-2-yl)-1 -oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide represented by the following structural formula-1.

The  present  invention  relates  to  novel  salts  of  2-(5-((pyrrolidin-l-ylsulfonyl)methyl)-lH-indol-3-yl)ethanamine, its use and process for their preparation.

Abstract The present invention relates to novel polymorph of (lS)-1,S-anhydro-1-[3-[[5—(4- fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol compound of formula-1, and its process for the preparation. thereof. The compound of formula-1 is represented by the following structural formula: ...

The  present invention  relates to  polymorphs  of 5-[[[(2S)-2-amino-3-[4-(amino carbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl] amino]methyl]-2-methoxybenzoic acid compound of formula-1, represented by the following structure: Formula-1

An improved process for the preparation of (S)-N, N-dimethyl-3-(naphthalen-l-yloxy)-l-phenylpropan-1-amine hydrochloride compound of formula-A.

The present invention related to novel crystalline forms of methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo    [2.2.1]hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4] hept-5-yl}-3-methyl-1-oxobutan-2-yl]carb...

The present invention related to a novel process for the preparation of (lR,2R,3aS,9aS)-[[2,3,3a,4,9,9a-Hexahydro-2-hydroxy-l-[(3S)-3-hydroxyoctyl]-lH-benz[fj inden-5-yl]oxy]acetic acid represented by structural formula-1 and also its pharmaceutically acceptable salts, preferably sodium salt represented by structura...

The  present  invention relates to  novel  polymorphs  of N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its process for the preparation.

The present invention relates to an oral pharmaceutical composition (-) modafinil.

Abstract The present invention relates to a novel polymorph of isobutyric acid 2-((R)-3-diisopropylamino-1 -phenylpropyl)-4-(hydroxymethyl)phenyl ester hydrochloride represented by the following structural formula-la and process for its preparation.

The present invention relates to process for the preparation of (ZS)-N-((S)-1-((S_)-4- methyl—1-((R)-2-methyloxiran-2-yl)-l-oxopentan-Z-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2- morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide represented by the following structural formula-1.

The present invention relates to a process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1 -[(2S)-1 -hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid represented by the following structural formula-1 and pharmaceutically acceptable salts thereof.

The present invention relates to amorphous form of N-[6-(cis-2,6-dimethylmorpholin- 4-yl)pyridine-3-yl]-2-methyl-4"-(trifluoromethoxy) [l,l"-biphenyl]-3-carboxamide diphosphate compound of formula-la and process for its preparation thereof, which is represented by the following structural formula CH3 F3C   (i ^ ...

The present invention provides processes for the preparation of (lS,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxyadamantan-l-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.

The present invention relates to an improved process for the preparation of (1S)-1,5-anhydro-1 -[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-P-glucitol compound of formula-1, represented by the following structural formula.

The present invention relates to process for the preparation of (4R,12aS)-9-{[(2,4-difluorophenyl)methyl]carbamoy [r,2,:4s5]pyrazino[2,l-b][l,3]pxazin-7-ol represented by the following structural formula-1 and pharmaceutical^ acceptable salts thereof.

The present invention relates to a novel crystalline form of anti-hyperuricemia drug, i.e. 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid represented by structure formula-1 and its process for preparation.

The present invention provides a process for the preparation of l-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-lH-indole-7-carboxamide compound represented by the following structural formula-1.

The present invention relates to a novel process for the preparation of crystalline l-(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino) propyl] -2,3-dihydro-lH-indole-7-carboxamide and its pharmaceutical composition.

The present invention relates to a process for the preparation of (S)-l0-acetoxy-10,11 -dihydro-5H-dibenz[b,fJazepine-5-carboxamide compound of formula-1.

The present invention relates to a process for the preparation of (2a,5p,7p,10p,13a)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-l-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-ll-en-2-yl benzoate compound of formula-1 and intermediates thereof. Formula-1 ...

The present invention relates to process for the preparation of D-glucitol, 1,5-anhydro-l-C-[4-chloro-3-[[4-[[(3,S)-tetrahydro-3-furanyl]oxy]phenyl] methyljphenyl]-, (IS) and its polymorphs of formula-1.

The present invention relates to an improved process for the preparation of 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-l-oxopropyl][(lS)-l-(4-phenyl-lH-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic   acid   compound   of  formula-1, represented by the following structure.

The present invention relates to novel and improved processes for the preparation of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1.

The present invention relates to a process for the preparation of an orally active renin  inhibitor  such  as  (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide compound of formula-1 or its salt thereof.

The present invention is directed to oral solid pharmaceutical dosage form comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-l,3-diol hydrochloride and method of making thereof.

ABSTRACT The present invention relates to novel crystalline polymorphs of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-l-piperazinyl)propoxy]-3-quinoline carbonitrile represented by the following structural formula-1 and process for preparation thereof.

The  present  invention provides  a novel  process  for the preparation of (lR,2R,3aS,9aS)-[[2,3,3a,4,9,9a-Hexahydro-2-hydroxy-l-[(3S)-3-hydroxyoctyl]-lH-benz[f]inden-5-yl]  oxy]acetic  acid  represented  by  structural  formula-1  and  its pharmaceutically acceptable acid addition salts, preferably its sodium salt ...

The present invention relates to process for the preparation of N-[5-(4-bromophenyl)- 6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N"-propylsulfamide   represented by the following structural formula-1.

The present invention relates to an improved process for the preparation of an orally active renin inhibitor such as (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyi-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide hemifumarate represented by the following structural formula-la. Furt...

The present invention provides novel polymorphic forms of (5-methyl-2-oxo-l,3-dioxol- 4-yl)methyl 2-ethoxy-1 - {[2"-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl] methyl}-lH-benzimidazole-7-carboxylic acid compound of formula-2, its derivatives and their pharmaceutically acceptable salts thereof. ...

ABSTRACT The present invention relates to‘ amorphous form of N-[2-[(1S)-1-(3-ethoxy—4- met_hoxyphenyl)-2-(methy1sulfonyl)ethy1]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide represented by the following structural forrnula-1 and process for its preparation.

Abstract; The present invention relates to an improved process for the preparation of ((2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1 yl)-1 -(1H-1,2,4-triazol-1 -yl)butan-2-ol) compound of formula-1, its salts and its crystalline forms thereof.

The present invention provides an improved process for the preparation of (S)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-l-pyrrolidinyl]-N-(2-pyrimidinyl methyl)-5-pyrimidine carboxamide which is represented by the following structural formula-1. Formula-1

The present invention relates to a process for the preparation of 1-Deoxy- l(methylamino)-D-glucitol [3-[[(2R,3S)-2-[(1R)-l-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)4-morpholinyl]methyl]-2,5-dihydro-5-oxo- 1H-1,2,4-triazol-1 -yl]phosphonate (2:1), having the following structural formula-1. ...

The present invention relates to an improved process for the preparation of propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-lH-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compound of formula-1, represented by the following structure:

The present invention relates to a process for the preparation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide compound of formula-1, and its crystalline polymorph-I which is represented by the following structural formula:

The present invention relates to novel crystalline polymorphs of l-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide represented by the following structural formula-1 a and process for preparation thereof.

The present invention relates to a process for the preparation (lR,5S)-N-[3-amino-1 -(cyclobutylmethyl)-2,3 -dioxopropyl]-3 - [2(S)- [ [ [(1,1 -dimethylethyl)amino] carbonyl]amino]-3,3-dimethyl-l-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide represented by structural formula-1. The present inventi...

The present invention relates to novel process for the preparation of (lS,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethyl butanoyl]-N-[(3 S)-1 -(cyclopropylamino)-1,2-dioxohexan-3 -yl]-3,3 a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-l-carboxamide compound represented...

The present invention relates to an improved process for the preparation of (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropionic acid and its intermediate compounds. The (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropionic acid is represented by the following structura...

The present invention relates to process for the préparation of N-[2-(7-methoxy-l - naphthyl)ethyl]acetamide compound of formula-1 and novel crystalline forms of its intermediate compounds.

Abstract The present invention relates to acid addition salts of 5-chloro-N4-[2-[(1-methylethyl) sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine and process for its preparation thereof compound of formula-1, represented by the following structure: ...

Abstract The present invention provides an improved process for the preparation of (±)-2-hydroxy-5-[( IRS)-1 -hydroxy-2-[[( lRS)-2-(4-methoxyphenyl)-1 methylethyl]-amino]ethyl] formanilide compound of formula-1 and its salts.

The present invention relates to a process for the preparation of intermediate compounds of(lR,5S)-N-[3-amino-l-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(l,l-dimethylethyl) amino]carbonyl]amino]-3,3-dimethyl-l-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide represented by structural formula-A....

The present invention provides an improved process for the preparation of antiarrhythmic agent represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof. Formula-1

The present invention relates to a pharmaceutical composition of N-(3,5-dichloropyridin-4-yl)-3 -cyclopropylmethoxy-4-difluoromethoxy-benzamide, which is useful for the treatment of chronic obstructive pulmonary disease (COPD).

The present invention is relates to an improved process for the preparation of (1S,4£7Z,10S,16£,21J?)^ tetraazabi- cyclo[8.7.6]tricos-16-ene-3,659,19,22-pentone of formula I

The present invention relates to an improved process for the preparation of N-[2-(7-methoxy-l-naphthyl)ethyl]acetamide, represented by the following structural formula-1. Further, the present invention also relates to novel process for the purification of intermediate compounds of said formula-1. Formula-1 ...

The present invention provides an improved process for the preparation of 2-ethylamino-4-methyl-4-phenyl-6-chloro-4H-3,l-benzoxazine compound represented by the following structural formula-1 and its pharmaceutically acceptable salts. Formula-1

Abstract The present invention relates to a process for the preparation of N-[2-hydroxy-5-[(lR)-l-hydroxy-2-[[(lR)-2(4-methoxyphenyl)-l-methylethyl]amino]ethyl] phenyl]-formamide tartrate compound of formula-1.

The present invention provides a stable crystalline form-B of 3-[(1R,2R)-3-(dimethylamino)-l-ethyl-2-methylpropyl]phenol mono hydrochloride compound of formula-la and its process for the preparation. Formula-la

The present invention relates to an improved process for the preparation of (R)-N-benzyl-2-Acetamido-3-methoxypropionamide compound of formula-1 represented as below

The present invention relates to improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2-oxo-3,4-dihydro-2H-quinolin-1-yl)methyl dodecanoate  compound  of  formula-1,  which  is  represented  by  the  following  structural formula

The present invention relates to an improved process for the preparation of Z-2-aminomethyl-1-phenyl-N,N-diethyl cyclopropane carboxamide compound of formula-1 and its pharmaceutically acceptable salts.

The present invention relates to solid state forms of 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N44-(2-methylphenyl)-6-(4-methylpiperazin-l-yl)pyridin-3-yl]propanamide represented by the following structural formula-1 and process for preparation thereof

The present invention relates to a novel process for the preparation of amorphous 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(lH-l,2,4-triazol-l-ylmethyl)-3furanyl]methoxy]phenyl]-l-piperazinyl]phenyl]-2-[(lS,2S)-l-ethyl-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one compound of formula-1. ...

The present invention relates to processes for the preparation of intermediate compounds, which are useful for the preparation of 8-[(3R)-3-amino-l-piperidinyl]-7-(2-butyn-l-yI)-3,7- dihydro-3-methyl-l-[(4-methyl-2-quinazolinyl)methyl]-lH-purine-2,6-dione compound represented by the following structural formula-1. ...

The present invention relates to an improved process for the preparation of 3-isobutyry] 2-isopropyl pyrazolo[l,5-a] pyridine compound represented by the structural formula-1

The present invention relates to an improved process for the preparation of ((3S,5R)-5-((lH-l,2,4-triazol-l-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl) methyl-4-methyl benzene sulfonate compound of formula-1 through novel intermediates.

The present invention relates to crystalline forms of Tapentadol salts and their processes for the preparation. The structural formula of Tapentadol salts is represented

The present invention relates to process for the preparation of (1S,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethylbutanoyl]-N-[(3 S)-1 -(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1 H-cyclopenta[c] pyrrole-1-carboxamide compound represented by the...

The present invention relates to acid-addition salts of (9RS)-3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)piperidin-l-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido [1,2-a] pyrimidin-9-yl hexadecanoate compound represented by the following structural formula-1, their polymorphs and processes for their preparation...

The present invention relates to novel crystalline form of N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide compound of formula-1 and process for its preparation.

represented by the following structural formula-1. The present invention also provides novel intermediate compounds useful for the preparation of compound of formula-1.

The present invention relates to an improved process for the preparation of (lR,5S)-N-[3-amino-l -(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(l ,1 -dimethyl ethyl)amino]carbonyl]amino]-3,3-dimethyl-l-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0] hexan-2(S)-carboxamide compound represented by the following structura...

The present invention relates to process for the preparation of 7-chloro-l-methyl-5-phenyl-lH-l,5-benzodiazepine-2,4(3H,5H)-dione represented by the following structural formula-1.

The present invention relates to novel process for the preparation of (Z)-isopropyl 7-((lR,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-l-enyl) cyclopentyl)hept-5-enoate represented by the compound of formula-I and its novel intermediates thereof.

The present invention relates to an improved process for the preparation of (±)-[ 1 R(S),2S(R)]-2-(aminomethyl)-N,N-diethyl-1 -phenylcyclopropane carboxamide, which is represented by the structural formula-1 and its pharmaceutically acceptable salts thereof.

The present invention relates to novel process for the preparation of 5-chloro-N4-[2-[(l-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(l-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine compound of formula-1 and its pharmaceutically acceptable salts thereof, represented by the following structure: ...

The present invention relates to a process for the preparation of anticoagulant drug i.e, 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl} methyl)-2-thiophene carboxamide represented by the following structural formula-1.   Formula-1

The present invention relates to a process for the preparation of antipsychotic drug i.e., (3aRS, 12bi?5)-5-Chloro-2-methyl-2,3,3a, 12b-tetrahydro-liMbenzo[2,3:6,7]oxepino [4,5-c]pyrrole maleate compound of formula-1.

The present invention relates to novel polymorph of metopimazine compound of formula-1 and process for it"s preparation.

The present invention relates to novel crystalline forms of antidepressant drug i.e., 5-[4-[4-(5-cyano- lH-indol-3-yl) butyl]-1 -piperazinyl]-2-benzofuran carboxamide compound of formula-1 represented by the following structural formula-1.

The present invention relates to novel and orally disintegrating sublingual pharmaceutical composition comprising asenapine and its pharmaceutically acceptable salts thereof, and methods of preparing the same. In particular, the invention relates to granulated pharmaceutical composition of asenapine and its salts th...

ABSTRACT The present invention relates to an improved process for the preparation of nebivolol hydrochloride compound of formula-1 And also relates to a novel organic acid salts of benzyl protected nebivolol compound offormuia-7.

The present invention relates to a novel process for the preparation of bosentan compound of formula-1.

The present invention relates to an improved process for the preparation of 1H- Benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-l -methyl-, monohydrochloride represented by the following structural formula-1.

The present invention relates to a novel process for the preparation of Dexlansoprazole compound of formula-1 and its pharmaceutically acceptable salts thereof.

The present invention relates to purification method for 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-ylcarboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide methanesulfonate represented by the following structural formula-1.

The present invention relates to stable parenteral pharmaceutical composition comprising of 3-[(li?,2i?)-3-(dimethylamino)-l-ethyl-2-methylpropyl]phenol or its pharmaceutically acceptable salts; preferably hydrochloride. Further, the present invention relates to a process for its preparation thereof. ...

The present invention relates to an improved process for the preparation of (R)-N-benzyl-2-Acetamido-3-inethoxypropionamide compound of formula-l represented by the following structural formula

The present invention relates to processes for the preparation of 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile represented by the following structural formula-1 and its pharmaceutically acceptable acid-addition salts.

The present invention provides an improved and novel processes for the preparation of 2-amino-2-[2-(4-octylphenyl)ethyl]propan-l,3-diol hydrochloride compound represented by the following structural formula-la.

The present invention relates to novel and improved processes for the preparation of sitagliptin compound of formula-1, its pharmaceutically acceptable salts as well as their intermediates. Formula-1

Novel process for the preparation of Moxifloxacin hydrochloride through novel quinoline amide intermediate. The present invention also relates to novel process for the preparation of anhydrous crystalline form-I of Moxifloxacin hydrochloride.

A process for the preparation of the Formula (VII) and pharmaceutically acceptable acid addition salts thereof, which comprises a) The esterification of Tetrahydro -2 -furoic acid (II) with methanol in presence of sulfuric acid b) Condensation of Methyl amino propyll,3-diamine (IV) with Tetrahydro -2- furo...

A novel process for the preparation of Fluvastatin and its intermediates Fluvastatin sodium of formula (I) is known as HMG-CoA reductase inhibitor

An improved process for the preparation of pantoptazole and its pharmaceutically acceptable salt compounds of general formula(5)

The present invention relates to an improved process for the preparation and purification of Pramipexole and its pharmaceutically acceptable salts, particularly pramipexole dihydrochloride monohydrate compound of formula-la as well as its intermediates. Pramipexole dihydrochloride monohydrate compound of formula-la ...

The present invention relates to an improved process for the preparation and purification of Trospium chloride as well as its intermediates. Trospium chloride compound of formula-1 is represented by the following structural formula

The present invention relates to an improved process for the preparation of dexlansoprazole. The present invention also relates to a process for the preparation of polymorphic forms of dexlansoprazole compound of formula-1 having the following structure.

The present invention provides an improved eco-friendly process for the preparation of memantine hydrochloride compound of formula-1. The present invention also provides a one-pot process for the preparation of memantine hydrochloride compound of fomula-1 from 1,3 -dimethyl adamantane without isolating any intermedi...

ABSTRACT The present invention relates to a novel process for the preparation of bosentan compound of formula-1.

The present invention relates to a novel process for the preparation of Sitagliptin compound of formula-1 and its pharmaceutically acceptable salts.

The present invention relates to an improved process for the preparation of prasugrel compound of formula-1 and its pharmaceutically acceptable salts thereof.

Industrial process for Alfuzosin hydrochloride compound of formula-1 represented as below

ABSTRACT The present invention relates to a novel and improved process for the preparation of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1 -lethal]-6,7,8 9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido-[ 1,2-a] pyrimidin-4-one (Paliperidone) represented by formula-1.

Title of the invention: An improved Process for the preparation of Clopidogrel Hydrogen bromide Clopidogrel hydrogen bromide shown below as Formula-I

ABSTRACT The present invention relates to an improved process for the preparation of highly pure pitavastatin and its pharmaceutically acceptable salts compound of general formula-] as well as their polymorphic forms.

The present invention relates to an improved process for the preparation of pure olmesartan medoxomil compound of formula-1,

The present invention relates to an improved process for the synthesis of bosentan. The process involves the preparation of p-tert-butyl-N-[6-halo-5-(2-methoxyphenoxy)[252'-bipyrimidin]-4-yl] benzenesulfonamide or its salt and its condensation with ethylene glycol in presence of a base and a suitable solvent with or...

The present invention relates to a new salt of a drug with an amine salt, characterized in that said amine is selected from the group consisting of amine of the following formula-1, Formula-1 Wherein each R1 and R2 are independently selected from a hydrogen atom, a straight or a branched alkyl group having 1 to 4 ...

The present invention relates to an improved process for the preparation of Aprepitant compound of formula-1 through a novel oxalate salt of 2(R)-[l-(R)-3,5-bis-(trifluoromethyl)phenyl)ethoxy]-3(S)"(4-fluoro phenyl) morpholine compound of formula-VII.

The present invention relates to an improved process for the preparation of pure ambrisentan compound of formula-1 through its novel amine salts. The present invention also relates to novel amine salts of {S)-2-hydroxy-3 -methoxy-3,3 -diphenylpropionic acid.

The present invention relates to an improved process for the preparation of high pure almotriptan compound of formula-1 and its pharmaceutically acceptable salts. The present invention also relates to novel polymorphs of almotriptan succinate and oxalate.

The present invention relates to a novel process for the preparation of methyl (+)-(S)-a-(o-cholorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetate benzene sulfonic acid (clopidogrel besylate) represented as a compound of formula-1.

The present invention relates to an improved process for the preparation of zileuton represented by the structural formula-1.

The present invention relates to an improved process for the preparation of solifenacin compound of formula-1 and its succinate salt compound of formula-la comprising condensation of (R)-3-quinuclidinol with (S)-ethyl-l-phenyl-1,2,3,4-tetrahydro-2-isoquinoline carboxylate in presence of a suitable inorganic base in ...

The present invention relates to novel process for the preparation of intermediate of GABA analogue represented by the following structural formula-1

The present invention relates to an improved process for the preparation of (R)-2-acetamido-N-benzyl-3-methoxypropionamide compound of formula-1 and also relates to process for its purification.

The present invention relates to novel and improved processes for the preparation of metopimazine compound of formula-1 and its pharmaceutically acceptable salts.

The present invention relates to novel process for the preparation of sitagliptin compound of formula-1 and its pharmaceutically acceptable salts. The present invention also relates to the recovery of sitagliptin intermediates from other isomer of sitagliptin and their usage.

The present invention relates to novel salts of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid and its intermediates used in the preparation of highly pure 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1.

The present invention relates to an improved process for the preparation of (R)-4-(2-(halomethyl)-3-methylbutyl)-l-methoxy-2-(3-methoxypropoxy) benzene compound of formula-1 and 3-amino-2,2-dimethylpropanamide compound of formula-12, useful intermediates in the synthesis of an orally active renin inhibitors. ...

The present invention relates to an improved process for the preparation of bosentan and its intermediate. The bosentan compound of formula-1 is represented by the following structural formula

The present invention is relates to polymorphs of bis[(E)-7-[4-(4- fluorophenyl)-6-iso-propyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt

The present invention relates to an improved process for the preparation of N-tert-buyl-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide and its intermediate.

The present invention relates to an improved process for the preparation of (3aRS, 12bRS)-5-Chloro-2-methyl-2,3,3a, 12b-tetrahydro- 1Hdibenzo[2,3:6,7] oxepino[4,5-c]pyrrole compound of formula-1 and its pharmaceutically acceptable salts.

ABSTRACT The present invention relates to an improved process for the preparation of ambrisentan compound of formula-1 and its intermediates as well as their polymorphs.

ABSTRACT The present invention relates to an improved process for the preparation of Darusentan compound of formula-1 and its polymorph.

The present invention relates to an improved process for the preparation of ranolazine compound of formula-1. It also relates to isolation and characterization of impurities, which are observed in the synthesis of ranolazine.

The present invention relates to  oral  solid pharmaceutical  composition of RS-4-[2-dimethylamino-l-(l-hydroxycyclohexyl)ethyl]phenol and process for preparing the same.

The present invention provides a novel salts of 3-cyclopropylmethoxy-4-difluoromethoxybenzoic acid and its use in the preparation of highly pure 3-cyclopropylmethoxy-4-difluoromethoxybenzoic acid, a useful intermediate in the preparation of 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)  be...

The present invention relates to a novel process for the preparation of ADP receptor inhibitors

The present invention relates to a process for the purification of deferasirox compound of formula-1.

A process for the preparation of 2-((4R,6S)-6-((E)-2-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)vinyl)-2,2-dimethyl-l,3-dioxan-4-yl) -N,N-disubstitutedacetamide compounds of general formula-1 containing low level of unwanted Z-isomer,wherein R and R" is independently selected from hy...

The present invention relates to process for the preparation of (R)-2-(4-methoxy-3-(3-methoxypropoxy) benzyl)-3-methylbutan-l-ol compound of formula-1, a useful intermediate in the synthesis of an orally active renin inhibitor.

The present invention relates to a novel solid pharmaceutical composition of dronedarone, its salts and process for preparing the same.

The present invention relates to novel and improved processes for the preparation of (R)-2-(3 -(diisopropylamino)-1 -phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.

An improved process for the preparation of 2-[3-cyano-4-(2- methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1. The present invention also provides the process for the preparation of crystalline forms A, B and G of compound of formula-1.

The present invention relates to an improved process for the preparation of trans- 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-lH-dibenz[2,3,6,7]oxepino[4,5c]pyrrol-l-one compound of formula-1. FIG.

The present invention relates to process for the preparation of l-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide methanesulfonate, represented by the following structural formula-1. Further, the present invention also provi...

The present invention relates to a process for the preparation of (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl propanamine represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.

The present invention relates to an improved process for the preparation of (R)-2-Acetamido-N-benzyl-3-methoxypropionamide represented by the following structural formula-1,

The present invention relates to an improved process for the preparation of antifungal drug i.e., 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluoro phenyl) tetrahydro-5-(lH-1,2,4-triazol-1 -ylmethyl)-3-furanyl]methoxy]phenyl]-1 -piperazinyl]phenyl]-2-[( 1 S,2S)-1 -ethyl-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one c...

The present invention relates to a process for the preparation of (Z)-7[(lR,2R,3R,5S)-3,5-dihydroxy-2-[(lE,3S)-3-hydroxy-5-phenyl-l-pentenyl]cyclopentyl] 5-N-ethylheptenamide compound of formula-1 represented by the following structural formula through a novel intermediate i.e., (3aR,4R,5R,6aS)-4-((lE,3S)-3-hydroxy-...

The present invention provides an improved process for the preparation of ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-4-yl)benzamido)propanoate compound of formula-7, which is a key intermediate in the synthesis of Dabigatran etexilate mesylate compound of formula-la. The present invention also provides salts of Dab...

The present invention relates to a non-hygroscopic amorphous free-flowing powder form of (±)-4"-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-l//-l-benzazepin-l-yl)carbonyl]-o-tolu-m-toluidide represented by the following structural formula-1 and process for its preparation.

The present invention relates to an improved process for the preparation of 2-ethoxy-1 - {[2"-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl} -1H-benzimidazole-7-carboxylic acid compound of formula-2, its derivatives and their pharmaceutically acceptable salts thereof.

The present invention relates to an improved process for the preparation of (3β )-17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate compound of formula-1 and its polymorphs. Formula-1

The present invention relates to novel process for the preparation of 2-[4-(2-{4-[l-(2- ethoxyethyl)-lH-beriziniidazol-2-yl]-l-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid represented by the following structural formula-1. Formula-1 The present invention also provides novel intermediate compounds useful for t...

The present invention relates to an improved process for the preparation of (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-fi-oxo-l-piperidine propanenitrile compound of formula-1 and its pharmaceutically acceptable salts.

Title of the invention: An improved process for the preparation of Alfuzosin hydrochloride (Formula I)

Title of the invention: An improved process for the preparation of Montelukast and its pharmaceutically acceptable salts Montelukast sodium (Formula-I) illustrated as below

One-Pot Synthesis for the preparation of Pantoprazole and its pharmaceutically acceptable salts Pantaprazole sodium (Formula-I) illustrated as below

An improved Process for the preparation of Clopidogrel and its pharmaceutically acceptable salts particularly Clopidogrel hydrogen chloride, Clopidogrel hydrogen bromide and Clopidogrel hydrogen sulfate Form-I.

The present invention relates to process for the preparation of D-glucitol 15- anhydro-l-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl] methyl]phenyl]- (1S) formula- 1 and its crystalline forms thereof.

The present invention relates to a process for the preparation of amorphous (1S)-1,5-anhydro-l-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol which is represented by the following structural formula-1:

The present invention relates to an improved process for the preparation of N-[4- [(3-chloro-4-fluoropheny1)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4- ‘(dimethyl amino_)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof.

The present invention relates to an improved process for the preparation of l- [(3 R)-3 -[4-amino-3 -(4-phenoxyphenyl)- l H-pyrazolo [3 ,4-d]pyrimidin- l -yl] - l -piperidin yl]-2-propen-1-one- compound of formulaél, which is‘represented by the following structural formula:

The present invention relates to a process for the preparation of amorphous (R)-3-(4-(7H-pyrrólo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitrile phosphate compound of formula-1 represented by the following structural formula:

The present invention relates to an improved process for the preparation of (R)-3-(4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitrile phosphate compound of formula-la, represented by the following structure:

The present invention relates to a process for the preparation of isobutyric acid 2-((R)-3-dissorpropylammounium-1-phenylpropyl)-4-(hydroxymethyl) phenyl ester represented by the following structural formula-1 and its pharmaceutically acceptable salts threof.

Abstract The present invention relates to crystalline 1,2-Propanediol solvate of N-(2-chloro-6-methylphenyl)-24[6-[4-(2-hydroxyethyl)-l-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5- thiazolecarboxamide compound of formula-1 and its process for the preparation.

The  present  invention  relates  to  amorphous  form  of  4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-l-piperazinyl)propoxy]-3-quinoline carbonitrile represented by the following structural formula-1 and process for its preparation.

A process for the preparation of anhydrous type I crystals of aripiprazole consistently. Aripiprazole is represented by the following structural formula-1.

The present invention relates to an improved process for the preparation of dihydroxy protected derivatives.

Abstract The present invention relates to an improved process for the preparation and purification of bosentan monohydrate compound of formula-1. The present invention also provides the preparation, isolation and characterization of 4-isopropyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2"-bipyrimidin-4-yl)-benz...

An improved process for pure Duloxetine hydrochloride compound of formula-1 represented as below

i : I 1 ' ABSTRACT ! . The present invention relates to novel processes for the preparation of (S)-isopropyl 2- ((S)-(((2R3MI^R)-5<2,4-dioxo metiiyltetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate represented by the following structural formula-land its novel polymorph. i "I ...

Abstract The .present invention relates to an improved process for the preparation of Prazosin hydrochloride compound of formula-la, its intermediate and their novel crystalline forms thereof.

The present invention relates to novel solvate of trityl olmesartan compound of formula-2 as well as an improved process for the preparation of highly pure olmesartan medoxomil compound of formula-1.

The present invention relates to an improved process for the preparation of deferasirox as well as a process for its purification. The present invention also relates to novel amine salts of deferasiox compound of general formula-8 and the process for their preparation.

The present invention relates to an improved process for the preparation of methyl 4,6- diaminoTZ-[l-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3 -y1]-5—pyrimidinyl(methyl)carbamate compound of formula-1 ,represented by the following structure:

The present invention relates to an improved process for the preparation of Azelastine compound of formula-1 and its pharmaceutically acceptable salts. Formula-1

The present invention relates to an improved process for the preparation of prasugrel and its pharmaceutically acceptable salts, especially hydrochloride compound of formula-la. The present invention also relates to novel salts of 5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,2-c]...

The present invention relates to an improved process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-l-(phenylmethyl)propyl]-carbamic acid (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl ester compound of formula-1 represented by the following structural formula: ...

The present invention provides a process for the preparation of form-XVI of 5-[4-[4-(5-cyano-1 H-indol-3-yl)butyl]-1 -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula-1 represented by the following structural formula. Formula-1

The present invention relates to novel salts of ethyl (3R,4S,5R)-4,5-imino-3-(l-ethylpropoxy)-l-cyclohexene-l-carboxylate compounds of formula-3 and an improved process for their preparation. The present invention also relates to improved process for the preparation of oseltamivir and its pharmaceutically acceptable...

The present invention relates to the processes for the preparation of (S)-5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-lH-benzimidazole sodium compound of formula-1 and bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-lH-benzimidazole-1-yl) magnesium dihydrate compound...

The present invention relates to an improved process for the preparation of [[2(S)-[[4(R)> (3-hydfbxyphen^ acid dihydrate, represented by the following structural formula:

The present invention relates to an improved process for the preparation of L3-bis(2-chloroethyl)-1 -nitrosourea compound of formual-1 which is represented by the following structural formula:

The present invention relates to an improved process for the preparation of N-[2-[(lS)-l-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-lJ3-dioxo-lH-isoindol-4-yl]acetamide represented by the following structural formula-1.

The present invention relates to an improved process for the preparation of 2-({6-[(3R)-3-aminopiperidin-1 -yl] -3 -methyl-2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl} methyl)benzonitrile represented by the following structural formula-1 and pharmaceutically acceptable salts thereof.

The present invention relates to a process for the preparation of 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula-la and its polymorphs thereof.X

The present invention relates to an improved process for the preparation of 11 -[(Z)-3-(dimethylamino)propylidene]-6,11 -dihydrodibenzo[b,e]oxepin-2-aceticacid compound of formula-1 and its pharmaceutically acceptable salts.

The present invention relates to an improved process for the preparation of 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-d^ yl}-2-fluoro-N-methylbenzamide compound of formula-1 represented by the following formula:

The present invention relates to an improved process for the preparation of 4-[[4-[[4-[(E)- 2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile monohydrochloride compound of formula-1a; represented by the following structural.

Abstract The present invention relates to acid addition salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4"-(trifluoromethoxy) [I,I"-biphenyl]-3-carboxamide compound of formula-1 and process for its preparation thereof. which is represented by the following structural formula ...

The present invention relates to novel crystalline polymorphs of l-[2-(2,4-dimethyl-phenylsulfanyl^phenylj-piperazine hydrobromide represented by the following structural formula-la and process for preparation thereof.

Abstract The present invention relates to crystalline forms of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4’-(trifluoromethoxy) [1,1’-biphenyl]-3-carboxamide phosphate salts and process for the preparation thereof, represented by the following structural formula:

The present invention relates to process for the preparation of methyl 4,6-diamino-2-[l-(2-fluorobenzyl)-lH-pyrazolo[354-b]pyridin-3-yl]-5-pyrirnidinyl(methyl)carbamate and its polymorphs thereof compound of formula-1, represented by the following structure:

A process for the preparation of crystalline form-N2 of 5-chloro-N4-[2-[(l-methylethyl) sulfonyl]phenyl] -N2- [5-methyl-2-(l -methylethoxy)-4-(4-piperidinyl)phenyl] -2,4- pyrimidinediamine acetic acid salt compound of formula-1b, comprising of the following steps: A a) Adding acetone to 5-chloro-N4-[2-[...

Abstract The present invention relates to an improved process for the preparation of (S)-N-[2-(l^.T^-tetrahydro^H-indeno-tS^-blfuran-S-yOethyllpropionamide compound of formula-1, represented by the following structural formula:

The present invention provides novel solid state forms of 2-((5-bromo-4-(4- cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid of formula (I) and its process for preparation thereof. The compound of formula (I) is represented by the following structural formula.

The present invention relates to an improved process for the preparation of methyl 4,6- diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate compound of formula-1, represented by the following structure:

The present invention relates to process for the preparation of amorphous (1S)-1,5-anhydro-l-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol compound of formula-1, represented by the following structural formula.

The present invention relates to novel crystalline polymorphs of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide represented by the following structural formula-1a and process for preparation thereof. Formula-1a

ABSTRACT Title: Co-amorphous form of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e] pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and process for its preparation thereof The present invention provides co-amorphous form of (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,...